Study shows Zebinix (eslicarbazepine acetate) is effective and well tolerated in epilepsy-Eisai

Once-daily Zebinix (eslicarbazepine acetate), from Eisai, in routine clinical practice demonstrates good retention rates and seizure control, and is well-tolerated when given as an add-on to anti-epileptic monotherapy in adults according to the primary results of the non-interventional EPOS study programme presented at the first Congress of the European Academy of Neurology. At six-months, the eslicarbazepine acetate retention rate was 82.2% and seizure freedom rate was at 39.2%.

Eslicarbazepine acetate is well tolerated with adverse events reported for 57 (26%) patients. Additional EPOS data presented at the congress demonstrates that eslicarbazepine acetate was effective, independent of the type of monotherapy treatment to which it was added. Retention rate at six months, time to eslicarbazepine acetate discontinuation and responder rate (response defined as ?50% seizure frequency reduction from baseline) were assessed according to the most frequent baseline monotherapies (>10% of patients).

Additional EPOS data for 104 patients in Germany reported retention rates of 86.5% and 44.7% of patients experiencing seizure freedom during the last three months of the study period. With the study investigators concluding that eslicarbazepine acetate as add-on to antiepileptic monotherapy is well-tolerated with high retention by the majority of adult patients in a real-life German population.